Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Campbell Soup Co. (CPB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Campbell Soup Co. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Campbell Soup Co. trades at $22.19 (market cap $6.83B). The key difference: Campbell Soup Co. is the larger of the two by market cap, and Campbell Soup Co. pays a 6.81% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | CPB | |
|---|---|---|
Market Cap | $4.49B | $6.83B |
Sector | Health | Consumer Staples |
52-Week High | $28.06 | $34.03 |
52-Week Low | $20.06 | $20.00 |
Enterprise Value | $3.69B | $13.44B |
Dividend Yield | — | 6.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Campbell's (CPB) trades at $22.90, down 1.8% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The stock offers a 7% dividend yield but faces margin pressures with net income margin at 6.12%. Recent Q1 2026 earnings beat expectations at $0.50 EPS, though sales declined 4% year-over-year. The company is implementing cost cuts and portfolio simplification while expanding through partnerships like the new gluten-free soup with Banza.
CPB presents a value opportunity with low P/E of 11.11 and P/S of 0.68, but faces structural challenges including margin deterioration and competitive pressures. Analyst consensus leans cautious with 55% hold ratings and $19.75 price target below current levels. The high dividend yield provides income support, but investors should monitor execution of cost-saving initiatives and consumer response to new product innovations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →
